CO earnings

Added 16,423 New Subscribers in 4QFY22 4QFY22 Revenues Down 1.7% YoY to RMB297.2 Million ($46.9 Million) 4QFY22 Gross Profit Down 0.5% YoY to RMB255.2 Million ($40.3 Million) 4QFY22 Operating Income Down 4.1% YoY to RMB142.1 Million ($22.4 Million) 4QFY22 Non-GAAP Operating Income Down 4.1% YoY to RMB153.9 Million ($24.3 Million) HONG KONG, July 5, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the fourth quarter and full year of fiscal 2022, ended March 31, 2022.

Added 18,985 New Subscribers in 3Q22Revenues Up 9.1% YoY to RMB317.2 Million ($49.8 Million)         Gross Profit Up 9.8% YoY to RMB269.9 Million ($42.4 Million)Operating Income Up 20.8% YoY to RMB149.7 Million ($23.5 Million) Non-GAAP Operating Income Up 18.6% YoY to RMB161.6 Million ($25.4 Million)Conference Call to be Held on March 1, 2022, at 8:00 a.m. ET HONG KONG, Feb. 28, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the third quarter and first nine month

HONG KONG, Feb. 23, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that it plans to release its financial results for the third quarter and first nine months of fiscal 2022 on Monday, February 28, 2022, after the U.S. market close.  The Company will host a conference call at 8:00 a.m. ET on Tuesday, March 1, 2022 to discuss its financial performance and give a brief overview of the Company's recent developments, followed by a question-and-answer session. Interested parties can access the audio webcast through

Added 19,066 New Subscribers in 2Q22Revenues Up 9.8% YoY to RMB313.7 Million ($48.7 Million)         Gross Profit Up 11.0% YoY to RMB267.5 Million ($41.5 Million)Operating Income Up 15.3% YoY to RMB160.5 Million ($24.9 Million) Non-GAAP Operating Income Up 14.1% YoY to RMB172.8 Million ($26.8 Million)Conference Call to be Held on November 26, 2021, at 8:00 a.m. ET HONG KONG, Nov. 24, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the second quarter and first half

HONG KONG, Nov. 17, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that it plans to release financial results for the second quarter and first half of fiscal 2022 on Wednesday, November 24, 2021, after the U.S. market close.  The Company will host a conference call at 8:00 a.m. ET on Friday, November 26, 2021 to discuss its financial performance and give a brief overview of the Company's recent developments, followed by a question-and-answer session. Interested parties can access the audio webcast through the

1Q22 Added 19,673 New SubscribersRevenues Up 12.2% YoY to RMB315.2 Million ($48.8 Million)Gross Profit Up 12.6% YoY to RMB267.3 Million ($41.4 Million)Operating Income Up 17.3% YoY to RMB156.6 Million ($24.2 Million)Non-GAAP Operating Income Up 15.5% YoY to RMB168.5 Million ($26.1 Million)Conference Call to be Held on August 31, 2021, at 8:00 a.m. ET HONG KONG, Aug. 30, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the first quarter of fiscal 2022, ended June 30

HONG KONG, Aug. 25, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that it plans to release financial results for the first quarter fiscal 2022 on Monday, August 30, 2021, after the market close.  The Company will host a conference call at 8:00 a.m. ET on Tuesday, August 31, 2021 to discuss its financial performance and give a brief overview of the Company's recent developments, followed by a question and answer session. Interested parties can access the audio webcast through the Company's IR website at http:

Added 19,367 New Subscribers in 4Q21Revenues Up 0.8% YoY to RMB302.3 million ($46.1 million)Net Income Attributable Up 31.7% YoY to RMB127.7 million ($19.5 million)Operating Cash Flow Up 134.6% YoY to RMB211.1 million ($32.2 million)Conference Call to be Held on June 29, 2021 at 8:00 a.m. ET HONG KONG, June 28, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the fourth quarter and full year of fiscal 2021, ended March 31, 2021. Fourth Quarter Fiscal 2021 Highlight

HONG KONG, Feb. 24, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the third quarter and first nine months of fiscal 2021, ended December 31, 2020. Third Quarter Fiscal 2021 Highlights Revenues decreased by 13.1% year-over-year ("YoY") to RMB290.8 million ($44.6 million). New subscribers and accumulated subscriber base were 17,802 and 882,982[1], respectively. Gross profit decreased by 13.1% YoY to RMB245.9 million ($37.7 million). Gross margin remained at 84.6